Desk note · industry · Healthcare manufacturing / industrial policy
India extended medical-device subsidies toward parts, not just finished kits
On 10 November 2026 the Department of Pharmaceuticals reopened the Production Linked Incentive scheme for medical devices through 2035-36 with about ₹2,700 crore of outlay, shifting PLI 2.0 toward critical components and high-end equipment as industry bodies warned device imports could cross ₹1 lakh crore this year.

- •Fresh applications under medical-device PLI 2.0 opened on 10 November 2026 with manufacturing incentives spread across consumables, critical components, advanced imaging gear, and equipment that is today only assembled domestically.
- •The revised programme removes minimum sales thresholds for claiming incentives, allows three years to commission projects, and offers differentiated rates where domestic capacity is thinnest.
- •Association of Indian Medical Device Industry coordinator Rajiv Nath said imports could exceed ₹1 lakh crore in 2026, making local component capacity a policy priority.
What's going on here?
Hospitals buy devices every week, but much of the bill still lands on imports when domestic plants only screw together foreign kits. On 10 November 2026, the Department of Pharmaceuticals invited new applications under an expanded Production Linked Incentive scheme for medical devices, extending support through 2035-36 with an outlay of about ₹2,700 crore. PLI 2.0 splits the money across four buckets: everyday consumables and implants, critical components, high-end machines where local manufacturing is still nascent, and equipment that today reaches Indian plants mainly as an assembly line. The government said the first phase since FY21 had already enabled production of more than 60 categories, including MRI systems, CT scanners, cath labs, and dialysis lines worth over ₹16,000 crore of output. Industry forums welcomed the reboot but stressed that the earlier version left gaps on components and shop-floor scale.
What does this mean?
Incentives now follow where import bills hurt most. Finished device lines got attention in PLI 1.0; version 2.0 tilts toward syringes, probes, and precision parts that hospitals reorder constantly. Longer implementation windows and no minimum sales hurdle lower the entry bar for mid-sized Indian manufacturers and for global firms willing to localise deeper than a single assembly hall. Poly Medicure managing director Himanshu Baid, quoted in the same reporting cycle, said differentiated rates match how hard each segment is to build. Higher support where import dependence is deepest can nudge capital toward tool rooms and sterile packaging, not only finished machines. Procurement rules, tariff bands, and a dedicated medtech regulator still matter as much as cash rebates, but the subsidy map now signals components first.
Why should I care?
Hospital procurement managers should track which domestic vendors qualify for PLI 2.0 before the next bulk tender, because accredited local lines can shorten spare-part lead times. Medtech entrepreneurs weighing a factory bet get a clearer list of eligible segments and timelines. Investors in listed device makers should read annual reports for capex tied to component lines, not only assembly margin. Watch how many applications file by the first compliance window, whether AiMeD and MTaI push for faster customs and procurement preference, and if import statistics for the December quarter show any early shift away from China and Vietnam on disposables.
More desk notes
Markets / GIFT IFSC
GIFT Nifty open interest set a fresh record above $22 billion
NSE International Exchange said on 19 November 2026 that GIFT Nifty open interest reached $22.21 billion on 18 November, topping the prior October peak as offshore index contracts keep drawing hedging and speculative flow at GIFT City.
Financial services / broking
Fairfax now owns more than half of IIFL Capital Services
FIH Mauritius Investments bought an 11.8% block from promoters on 19 November 2026 for about ₹1,540 crore, lifting the Fairfax group's combined holding in IIFL Capital Services Ltd past 50% as it funds the IDBI Bank takeover.
Power transmission
Adani Energy won a Bihar link for a 2,400 megawatt power plant
Adani Energy Solutions Ltd secured a tariff-based transmission project on 19 November 2026 to evacuate power from the 2,400 MW Pirpainti thermal plant in Bihar, adding 881 circuit kilometres and about ₹500 crore of annual regulated revenue when the lines go live by late 2028.
Consumer durables / travel goods
VIP Industries is pushing premium luggage after two growth quarters
Managing director Atul Jain said on 19 November 2026 that VIP Industries grew consolidated revenue 15% in the September quarter, narrowed losses, and leaned on premium SKUs, roughly 65 new ranges, and wider retail reach while passing three price hikes totalling 7–8% in six months.
For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.